{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=106&state=Wisconsin",
    "query": {
      "state": "Wisconsin",
      "city": "Milwaukee",
      "page": 106
    },
    "page_size": 10
  },
  "pagination": {
    "page": 106,
    "page_size": 10,
    "total_count": 5363,
    "total_pages": 537,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=107&state=Wisconsin&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Milwaukee&page=105&state=Wisconsin&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-21T04:17:03.297Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04471727",
      "title": "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Small-Cell Lung Cancer",
        "Neuroendocrine Carcinoma"
      ],
      "interventions": [
        {
          "name": "Gocatamig",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Atezolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ifinatamab Deruxtecan (I-DXd)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 232,
      "start_date": "2020-12-14",
      "completion_date": "2028-01-28",
      "has_results": false,
      "last_update_posted_date": "2026-02-24",
      "last_synced_at": "2026-11-21T04:17:03.297Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04471727"
    },
    {
      "nct_id": "NCT05013229",
      "title": "A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "IcoSema",
          "type": "DRUG"
        },
        {
          "name": "Insulin glargine",
          "type": "DRUG"
        },
        {
          "name": "insulin aspart",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novo Nordisk A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 679,
      "start_date": "2021-11-30",
      "completion_date": "2023-11-14",
      "has_results": false,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-11-21T04:17:03.297Z",
      "location_count": 66,
      "location_summary": "Guntersville, Alabama • Fresno, California • La Jolla, California + 59 more",
      "locations": [
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Lomita",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05013229"
    },
    {
      "nct_id": "NCT00312845",
      "title": "Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Hodgkin's Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bortezomib + Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 676,
      "start_date": "2006-03",
      "completion_date": "2010-07",
      "has_results": true,
      "last_update_posted_date": "2012-06-25",
      "last_synced_at": "2026-11-21T04:17:03.297Z",
      "location_count": 41,
      "location_summary": "Opelika, Alabama • Alhambra, California • Bakersfield, California + 36 more",
      "locations": [
        {
          "city": "Opelika",
          "state": "Alabama"
        },
        {
          "city": "Alhambra",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00312845"
    },
    {
      "nct_id": "NCT02063672",
      "title": "Lutonix® Drug Coated Balloon vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Femoral Artery Stenosis",
        "Femoral Artery Occlusion",
        "Restenosis"
      ],
      "interventions": [
        {
          "name": "Lutonix DCB",
          "type": "DEVICE"
        },
        {
          "name": "Standard Uncoated Balloon Angioplasty Catheter",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "C. R. Bard",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2014-03",
      "completion_date": "2019-03",
      "has_results": true,
      "last_update_posted_date": "2019-04-11",
      "last_synced_at": "2026-11-21T04:17:03.297Z",
      "location_count": 20,
      "location_summary": "Fairhope, Alabama • New Haven, Connecticut • Washington D.C., District of Columbia + 17 more",
      "locations": [
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02063672"
    },
    {
      "nct_id": "NCT02372877",
      "title": "Evaluation of the AMICUS RBCx System in Sickle Cell Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Sickle Cell Anemia"
      ],
      "interventions": [
        {
          "name": "Amicus Red Cell Exchange in SCD patients",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Fenwal, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 83,
      "start_date": "2015-05",
      "completion_date": "2018-01-19",
      "has_results": true,
      "last_update_posted_date": "2022-07-29",
      "last_synced_at": "2026-11-21T04:17:03.297Z",
      "location_count": 6,
      "location_summary": "Phoenix, Arizona • Detroit, Michigan • St Louis, Missouri + 3 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02372877"
    },
    {
      "nct_id": "NCT00003775",
      "title": "Leflunomide in Treating Patients With Anaplastic Astrocytoma in First Relapse",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "leflunomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "1998-12",
      "completion_date": "2006-05",
      "has_results": false,
      "last_update_posted_date": "2012-09-13",
      "last_synced_at": "2026-11-21T04:17:03.297Z",
      "location_count": 22,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 18 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Miami Beach",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003775"
    },
    {
      "nct_id": "NCT02151981",
      "title": "AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anticancer Treatment"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Cross-over to Osimertinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 421,
      "start_date": "2014-08-04",
      "completion_date": "2023-12-15",
      "has_results": true,
      "last_update_posted_date": "2025-01-07",
      "last_synced_at": "2026-11-21T04:17:03.297Z",
      "location_count": 21,
      "location_summary": "Anaheim, California • Orange, California • Santa Rosa, California + 18 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02151981"
    },
    {
      "nct_id": "NCT02610283",
      "title": "A Study to Evaluate Efficacy and Safety of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [
        {
          "name": "QPI-1002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Quark Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 341,
      "start_date": "2015-12",
      "completion_date": "2018-04",
      "has_results": false,
      "last_update_posted_date": "2019-01-10",
      "last_synced_at": "2026-11-21T04:17:03.297Z",
      "location_count": 20,
      "location_summary": "Tucson, Arizona • Gainesville, Florida • Jacksonville, Florida + 16 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Oak Lawn",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02610283"
    },
    {
      "nct_id": "NCT00304031",
      "title": "Radiation Therapy (RT) and Temozolomide (TMZ) in Treating Patients With Newly Diagnosed Glioblastoma or Gliosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors"
      ],
      "interventions": [
        {
          "name": "Concurrent temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Concurrent radiation therapy",
          "type": "RADIATION"
        },
        {
          "name": "100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle",
          "type": "DRUG"
        },
        {
          "name": "75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Radiation Therapy Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 1173,
      "start_date": "2006-01",
      "completion_date": "2016-12",
      "has_results": true,
      "last_update_posted_date": "2020-06-09",
      "last_synced_at": "2026-11-21T04:17:03.297Z",
      "location_count": 341,
      "location_summary": "Fairbanks, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 240 more",
      "locations": [
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Auburn",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00304031"
    },
    {
      "nct_id": "NCT01452802",
      "title": "Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Heart Failure"
      ],
      "interventions": [
        {
          "name": "HM II (HeartMate II LVAD)",
          "type": "DEVICE"
        },
        {
          "name": "OMM (Optimal Medical Management)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Abbott Medical Devices",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 200,
      "start_date": "2011-10",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2022-06-24",
      "last_synced_at": "2026-11-21T04:17:03.297Z",
      "location_count": 52,
      "location_summary": "Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 41 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01452802"
    }
  ]
}